Bengaluru, January 15, 2026 – Biocon Limited (BSE: 532523 | NSE: BIOCON) on Wednesday announced the successful allotment of equity shares under its recently concluded institutional fundraise, mobilising ₹4,150 crore to strengthen its balance sheet and support long-term growth initiatives.
Issue Details and Fundraise Summary
The company approved the issue and allotment of 11,26,64,585 equity shares of face value ₹5 each at an issue price of ₹368.35 per share, including a premium of ₹363.35 per share. The institutional placement opened on January 12, 2026, and closed on January 14, 2026.The total amount raised through the transaction aggregates to ₹4,150 crore.
Key Issue Particulars
| Particulars | Details |
|---|---|
| Securities issued | Equity shares |
| Number of shares allotted | 11,26,64,585 |
| Issue price | ₹368.35 per share |
| Face value | ₹5 per share |
| Total proceeds | ₹4,150 crore |
Impact on Share Capital
Following the allotment, Biocon’s paid-up equity share capital increased from ₹754.12 crore, comprising 150.82 crore equity shares, to ₹810.45 crore, comprising 162.09 crore equity shares of face value ₹5 each.Share Capital Position
| Particulars | Before Issue | After Issue |
|---|---|---|
| Paid-up equity capital | ₹754.12 crore | ₹810.45 crore |
| Number of equity shares | 150.82 crore | 162.09 crore |
Institutional Participation Highlights
The issue saw participation from several large domestic mutual fund schemes, with select funds receiving more than 5 percent of the equity shares offered in the transaction. Major allocations were seen across diversified, value, healthcare-focused, and large-and-midcap oriented schemes, reflecting continued institutional confidence in Biocon’s long-term business prospects.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.